PureTech Health Plc

Research PureTech Health Plc (PRTC) on Bullrun: market cap USD 407.58M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPRTC
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 407.58M
• Financial periodQ4 2025
• RevenueUSD 4.66M
• Net income-USD 109.74M
• Free cash flow-USD 85.14M

Valuation Snapshot

latest market cap is USD 407.58M.

About PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression;

Frequently asked questions

What is PureTech Health Plc's market cap?

PureTech Health Plc's market capitalization is USD 407.58M.

What does PureTech Health Plc do?

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF);